MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Metrics to compare | MEDCL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMEDCLPeersSector | |
---|---|---|---|---|
P/E Ratio | −30.9x | 16.1x | −0.6x | |
PEG Ratio | −1.06 | −0.05 | 0.00 | |
Price/Book | −34.9x | 2.8x | 2.6x | |
Price / LTM Sales | 20.6x | 3.2x | 3.3x | |
Upside (Analyst Target) | 27.0% | 85.6% | 39.1% | |
Fair Value Upside | Unlock | 14.2% | 5.4% | Unlock |